Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
OXYGEN, USP is a respiratory gas therapeutic administered via inhalation for patients requiring supplemental oxygen therapy. The product addresses critical respiratory insufficiency across acute and chronic care settings. It is a non-drug gas product essential for maintaining adequate tissue oxygenation in vulnerable patient populations.
At peak lifecycle stage with moderate competitive pressure (30), indicating a mature, stable market with limited team expansion opportunities.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safety Study of Intravenous Hydrogen-Oxygen Ultrafine Bubbles in Adults
Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants
MolecuLight All-in-One Oxygenation Clinical Utility
Endoscopic COlorectal Mucosal Evaluation of Oxygen Tension
Impact of Intraoperative Oxygenation Practices on Patient Outcomes
Worked on OXYGEN, USP at Universal Cells? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on OXYGEN, USP offers a small, specialized career footprint with only 2 linked positions, primarily in design and open roles at Universal Cells. This limited opportunity set reflects the mature, commodity nature of the product and suggests niche roles in supply-chain design, regulatory operations, or specialized commercial functions rather than core brand management or field operations.
2 open roles linked to this drug